MACROGENICS INC 8-K

What Happened

• MacroGenics filed an 8-K reporting that on May 1, 2026 it entered into a First Amendment with an affiliate of Sagard Healthcare Partners to the June 9, 2025 Royalty Purchase Agreement for royalties on ZYNYZ (retifanlimab-dlwr).
• Under the amendment MacroGenics received an additional $60.0 million, bringing the total purchase price to $130.0 million, and the parties revised the capped royalty interest and related payback triggers.

Key Details

• Cash received: $60.0 million on May 1, 2026; Aggregate Purchase Price is now $130.0 million.
• Royalty cap/reversion: Sagard’s royalty rights will revert to MacroGenics once Sagard has received either 1.70x the Aggregate Purchase Price by September 30, 2032, or 2.0x the Aggregate Purchase Price at any time thereafter.
• Additional milestone: MacroGenics is eligible for a one-time payment up to $20.0 million if ZYNYZ meets specified 2026 sales thresholds; any such payment would be added to the Aggregate Purchase Price for calculating the royalty cap.
• MacroGenics retains other economic interests in ZYNYZ (future development, regulatory, commercial milestones) and the amendment contains customary representations, covenants and indemnities.

Why It Matters

• Immediate liquidity: The $60M cash payment strengthens MacroGenics’ near-term cash position.
• Changes future revenue profile: The amendment limits Sagard’s upside via a defined payback multiple, meaning royalties could revert to MacroGenics once Sagard reaches those return thresholds; a possible additional $20M milestone could extend Sagard’s capped return.
• Continued exposure to ZYNYZ performance: Future cash from royalties and any milestone depends on ZYNYZ global sales, so actual payments remain tied to commercial outcomes. The company filed a press release and included forward‑looking statement disclaimers about sales, milestones and risks.